Findings

What does this study add?

• Average monthly headache days were significantly reduced by 43% from baseline following initiation of onabotulinumtoxinA treatment alone.
• OnabotulinumtoxinA plus a CGRP mAb medication significantly reduced average monthly headache days by 65.6% from baseline.
• CGRP mAb medications were well-tolerated with 8.5% of patients reporting side effects that included constipation, injection site reaction, and/or fatigue.